Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. (10th September 2018)

• Record Type: Journal Article
• Authors: Armstrong, A J; Lin, P; Higano, C S; Sternberg, C N; Sonpavde, G; Tombal, B; Templeton, A J; Fizazi, K; Phung, D; Wong, E K; Krivoshik, A; Beer, T M
• Is Part Of: Annals of oncology. Volume 29:Number 11(2018)
• Page Start: 2200
• Page End: 2207
• Publication Date: 2018-09-10
• Subjects: prognostic variables -- overall survival -- nomogram -- enzalutamide -- metastatic castration-resistant prostate cancer -- multivariable model; Oncology -- Periodicals; 616.992
• DOI: 10.1093/annonc/mdy406
• Languages: English
• ISSNs: 0923-7534

Abstract

Abstract: Background: Prognostic models are needed that reflect contemporary practice for men with metastatic castration-resistant prostate cancer (mCRPC). We sought to identify predictive and prognostic variables for overall survival (OS) in chemotherapy-naïve men with mCRPC treated with enzalutamide. Patients and methods: Patients from the PREVAIL trial database (enzalutamide versus placebo) were randomly split 2 : 1 into training ( n = 1159) and testing ( n = 550) sets. Using the training set, 23 predefined variables were analyzed and a multivariable model predicting OS was developed and validated in an independent testing set. Results: Patient characteristics and outcomes were well balanced between training and testing sets; median OS was 32.7 months in each. The final validated multivariable model included 11 independent prognostic variables. Median OS for low-, intermediate-, and high-risk groups (testing set) defined by prognostic risk tertiles were not yet reached (NYR) (95% CI NYR–NYR), 34.2 months (31.5–NYR), and 21.1 months (17.5–25.0), respectively. Hazard ratios (95% CI) for OS in the low- and intermediate-risk groups versus high-risk group were 0.20 (0.14–0.29) and 0.40 (0.30–0.53), respectively. Secondary outcomes of response and progression differed widely in model-defined risk groups. Enzalutamide improved outcomes in all prognostic risk groups. Conclusions: Our validated prognostic model incorporates variables routinely collected in chemotherapy-naïve men with mCRPC treated with enzalutamide, identifying subsets of patients with widely differing survival outcomes that provide useful information for external validation, patient care, and clinical trial design. Trial registration: ClinicalTrials.gov: NCT01212991.